
Medium-High-Risk
Early Breast Cancer
N = 3500
Randomization and Blinding
1 : 1
Standard Surveillance
Guideline-based Standard Follow-Up
+ blood drawls (biobank)
N = 1750
Intensive Surveillance
Guideline-based Standard Follow-Up
+ Liquid-Biopsy based Follow-Up
(Tumor Marker, CTC, ctDNA)
N = 1750
Metastasis-specific Symptoms
Detection of minimal residual Disease
OR Metastasis-specific Symptoms
Staging Examinations
M1
M0
Guideline-based Diagnostic
Measures and Therapy